CTOs on the Move

Medcura Incorporated

www.medcurainc.com

 
Medcura, Inc. has developed an advanced wound care platform that can be used across a broad spectrum of clinical and non-clinical settings. By making molecular modifications to natural biopolymers, Medcura`s patented approach provides rapid hemostasis in a clean, safe healing environment. The company has achieved milestones such as 3 FDA Clearances, 6 issued patents, and 7 peer-reviewed publications.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.medcurainc.com
  • 5650 Rivertech Court Suite South
    Riverdale, MD USA 20737
  • Phone: 240.684.8801

Executives

Name Title Contact Details

Similar Companies

Smith-Sterling Dental Laboratories

Smith-Sterling Dental Laboratories is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rare Cancer Research Foundation

The Rare Cancer Research Foundation (RCRF) is dedicated to curing rare cancers through strategic investments and innovative collaborations that catalyze effective research and accelerate deployment of promising therapies. While rare cancers accounted for just over 25 percent of all new cancer diagnoses in 2013, they comprised more than 40 percent of all cancer deaths. RCRF`s goal is to develop research infrastructure for each rare cancer.

Delinia

Delinia has assembled a leadership team, Board of Directors and Scientific Advisory Board comprised of experienced investors, world-class academicians and industry veterans with proven track records for building exceptional life sciences companies.

Epinex Diagnostics

Epinex Diagnostics is a Tustin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

X-Vax Technology

We`re a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes. Our research leads us to believe that the new approach we`re taking could succeed in defeating herpes by inducing antibodies that mediate the killing of infected cells. We`re strongly committed to this fight, and so far our work has been supported with unprecedented data in multiple preclinical models.